US FDA grants priority review status to AstraZeneca & Daiichi Sankyo's sBLA for Enhertu for patients with HER2─low or ...
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-low ( …